R&D | April 29, 2026
Evonik and Higuchi launch “Open Pharma Lab” in Yokohama to accelerate oral drug Innovation
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
After Phase 3 results show major hair regrowth gains
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Subscribe To Our Newsletter & Stay Updated
